Form 4: Cue Biopharma Director Michael J. Fox Acquires Stock Options

Director Michael J. Fox acquired stock options in Cue Biopharma, Inc. on June 5, 2024.

Summary

• Michael J. Fox, a director of Cue Biopharma, Inc., filed a Form 4 on June 7, 2024, reporting a transaction.
• On June 5, 2024, Fox acquired stock options to purchase 48,800 shares of Cue Biopharma's common stock at an exercise price of $1.65 per share.
• The options vest over three years, with one-third vesting on the one-year anniversary of the grant date and the remainder vesting in eight equal quarterly installments.
• Following the transaction, Fox directly owns 48,800 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• Shareholders may view the stock option grant as an incentive for the director to work towards increasing shareholder value.

Key Dates